Advances in the preclinical testing of cancer therapeutic hypotheses
The DOI matches its Crossref record; 88 of the 89 references it cites were found in a registry or an index.
Abstract
The genetic and epigenetic underpinnings of cancer are becoming increasingly clear owing to impressive and well-coordinated ventures occurring worldwide. As our understanding of the molecular alterations driving human cancer increases, there is an opportunity to direct the clinical application of cancer therapeutics with improved accuracy. The often empirical treatment of cancer--which was initially based on inhibiting DNA synthesis and cellular division--while having led to a number of remarkable successes, remains prone to a high rate of clinical failure that results partly from a lack of understanding of how best to implement drugs in the clinic. Consequently, it is vital that robust translational strategies be developed preclinically to both reduce failure rates in the clinic and shorten the time required to identify patient populations most likely to benefit from a given therapeutic. Here, we review both historical and current uses of preclinical model systems, being mindful that a combination of approaches will be needed to address all meritorious therapeutic hypotheses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 1×
“Such mutations were initially identified through the study of samples taken from patients with relapsed diseas”
BackgroundOlive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681 · cited 1×
“, as well as a variety of lesions in oncogenic driver genes including KRAS , epidermal growth factor receptor ( EGFR ), phosphoinositide 3-kinase, catalytic, alpha polypeptide (PI3KCA) and anaplastic lymphoma receptor tyrosine kinase (ALK), among other”
BackgroundThe NCI60 human tumour cell line anticancer drug screen
Shoemaker, R. H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1951 · Cited by 2,620
International network of cancer genome projects
The International Cancer Genome Consortium (2010) · Nature · doi:10.1038/nature08987 · Cited by 2,299
Chemotherapy and the war on cancer
Chabner, B. A., & Roberts, T. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1529 · Cited by 2,154
Systematic variation in gene expression patterns in human cancer cell lines
Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., Spellman, P., Iyer, V., Jeffrey, S. S., Van de Rijn, M., Waltham, M., et al. (2000) · Nature Genetics · doi:10.1038/73432 · Cited by 2,088
A History of Cancer Chemotherapy
DeVita, V. T., & Chu, E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6611 · Cited by 1,970
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
Shaw, A. T., Yeap, B. Y., Mino-Kenudson, M., Digumarthy, S. R., Costa, D. B., Heist, R. S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6993 · Cited by 1,870
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,831
Efficient tumour formation by single human melanoma cells
Quintana, E., Shackleton, M., Sabel, M. S., Fullen, D. R., Johnson, T. M., & Morrison, S. J. (2008) · Nature · doi:10.1038/nature07567 · Cited by 1,796
Fluorinated pyrimidines, a new class of tumour-inhibitory compounds
HEIDELBERGER, C., CHAUDHURI, N. K., DANNEBERG, P., MOOREN, D., GRIESBACH, L., DUSCHINSKY, R., SCHNITZER, R. J., PLEVEN, E., & SCHEINER, J. (1957) · Nature · doi:10.1038/179663a0 · Cited by 1,603
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548
Self-citationA gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
BRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328
Self-citationAn Information-Intensive Approach to the Molecular Pharmacology of Cancer
Weinstein, J. N., Myers, T. G., O'Connor, P. M., Friend, S. H., Fornace, A. J., Kohn, K. W., Fojo, T., Bates, S. E., Rubinstein, L. V., Anderson, N. L., et al. (1997) · Science · doi:10.1126/science.275.5298.343 · Cited by 1,183
Characterizing the cancer genome in lung adenocarcinoma
Weir, B. A., Woo, M. S., Getz, G., Perner, S., Ding, L., Beroukhim, R., Lin, W. M., Province, M. A., Kraja, A., Johnson, L. A., et al. (2007) · Nature · doi:10.1038/nature06358 · Cited by 1,105
Beroukhim, R., Getz, G., Nghiemphu, L., Barretina, J., Hsueh, T., Linhart, D., Vivanco, I., Lee, J. C., Huang, J. H., Alexander, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710052104 · Cited by 1,075
Self-citationPreexistence and clonal selection of MET amplification in EGFR mutant NSCLC
Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059
Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Druker, B. J., & Lydon, N. (1996) · PubMed · Cited by 1,057
EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
Koivunen, J. P., Mermel, C., Zejnullahu, K., Murphy, C., Lifshits, E., Holmes, A. J., Choi, H. G., Kim, J., Chiang, D., Thomas, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0168 · Cited by 993
A paracrine requirement for hedgehog signalling in cancer
Yauch, R. L., Gould, S. E., Scales, S. J., Tang, T., Tian, H., Ahn, C. P., Marshall, D., Fu, L., Januario, T., Kallop, D., et al. (2008) · Nature · doi:10.1038/nature07275 · Cited by 961
Tumor Growth Need Not Be Driven by Rare Cancer Stem Cells
Kelly, P. N., Dakic, A., Adams, J. M., Nutt, S. L., & Strasser, A. (2007) · Science · doi:10.1126/science.1142596 · Cited by 827
The Biological Actions and Therapeutic Applications of the B-Chloroethyl Amines and Sulfides
Gilman, A., & Philips, F. S. (1946) · Science · doi:10.1126/science.103.2675.409 · Cited by 732
Engelman, J. A., & Jänne, P. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2248 · Cited by 703
GOODMAN, L. S. (1946) · Journal of the American Medical Association · doi:10.1001/jama.1946.02870380008004 · Cited by 700
Rodig, S. J., Mino-Kenudson, M., Dacic, S., Yeap, B. Y., Shaw, A., Barletta, J. A., Stubbs, H., Law, K., Lindeman, N., Mark, E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0802 · Cited by 678
The mighty mouse: genetically engineered mouse models in cancer drug development
Sharpless, N. E., & DePinho, R. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2110 · Cited by 661
Systematic discovery of multicomponent therapeutics
Borisy, A. A., Elliott, P. J., Hurst, N. W., Lee, M. S., Lehár, J., Price, E. R., Serbedzija, G., Zimmermann, G. R., Foley, M. A., Stockwell, B. R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1337088100 · Cited by 620
THE VINCA ALKALOIDS: A NEW CLASS OF ONCOLYTIC AGENTS.
JOHNSON, I. S., Jg, A., Gorman, M., & Jp, B. (1963) · PubMed · Cited by 564
Buonamici, S., Williams, J., Morrissey, M., Wang, A., Guo, R., Vattay, A., Hsiao, K., Yuan, J., Green, J., Ospina, B., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001599 · Cited by 562
Self-citationLandscaping the Cancer Terrain
Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.280.5366.1036 · Cited by 516
A mouse model for EML4-ALK -positive lung cancer
Soda, M., Takada, S., Takeuchi, K., Choi, Y. L., Enomoto, M., Ueno, T., Haruta, H., Hamada, T., Yamashita, Y., Ishikawa, Y., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805381105 · Cited by 512
PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
Wee, S., Jagani, Z., Xiang, K. X., Loo, A., Dorsch, M., Yao, Y.-M., Sellers, W. R., Lengauer, C., & Stegmeier, F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4765 · Cited by 455
Self-citationDanila, D. C., Morris, M. J., de Bono, J. S., Ryan, C. J., Denmeade, S. R., Smith, M. R., Taplin, M.-E., Bubley, G. J., Kheoh, T., Haqq, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9259 · Cited by 410
Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis
Tian, H., Callahan, C. A., DuPree, K. J., Darbonne, W. C., Ahn, C. P., Scales, S. J., & de Sauvage, F. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813203106 · Cited by 404
Klein, K. A., Reiter, R. E., Redula, J., Moradi, H., Zhu, X. L., Brothman, A. R., Lamb, D. J., Marcelli, M., Belldegrun, A., Witte, O. N., et al. (1997) · Nature Medicine · doi:10.1038/nm0497-402 · Cited by 399
McDermott, U., Iafrate, A. J., Gray, N. S., Shioda, T., Classon, M., Maheswaran, S., Zhou, W., Choi, H. G., Smith, S. L., Dowell, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6186 · Cited by 399
Ryan, C. J., Smith, M. R., Fong, L., Rosenberg, J. E., Kantoff, P., Raynaud, F., Martins, V., Lee, G., Kheoh, T., Kim, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.1281 · Cited by 396
Reid, A. H. M., Attard, G., Danila, D. C., Oommen, N. B., Olmos, D., Fong, P. C., Molife, L. R., Hunt, J., Messiou, C., Parker, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.6819 · Cited by 394
Davies, B. R., Logie, A., McKay, J. S., Martin, P., Steele, S., Jenkins, R., Cockerill, M., Cartlidge, S., & Smith, P. D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0231 · Cited by 387
GDC-0449—A potent inhibitor of the hedgehog pathway
Robarge, K. D., Brunton, S. A., Castanedo, G. M., Cui, Y., Dina, M. S., Goldsmith, R., Gould, S. E., Guichert, O., Gunzner, J. L., Halladay, J., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.08.049 · Cited by 386
Bai, R. L., Paull, K. D., Herald, C. L., Malspeis, L., Pettit, G. R., & Hamel, E. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98491-7 · Cited by 379
Development of the Proteasome Inhibitor PS-341
Adams, J. (2002) · The Oncologist · doi:10.1634/theoncologist.7-1-9 · Cited by 369
Wakimoto, H., Kesari, S., Farrell, C. J., Curry, W. T., Zaupa, C., Aghi, M., Kuroda, T., Stemmer-Rachamimov, A., Shah, K., Liu, T.-C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3886 · Cited by 361
McDermott, U., Sharma, S. V., Dowell, L., Greninger, P., Montagut, C., Lamb, J., Archibald, H., Raudales, R., Tam, A., Lee, D., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707498104 · Cited by 356
Zhao, X., Weir, B. A., LaFramboise, T., Lin, M., Beroukhim, R., Garraway, L., Beheshti, J., Lee, J. C., Naoki, K., Richards, W. G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4603 · Cited by 337
Self-citationVCaP, a cell-based model system of human prostate cancer.
Korenchuk, S., Lehr, J. E., McLean, L. L., Lee, Y.-G., Whitney, S. C., Vessella, R. L., Lin, D. L., & Pienta, K. J. (2001) · PubMed · Cited by 323
Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor.
Rong, S., Bodescot, M., Blair, D., Dunn, J., Nakamura, T., Mizuno, K., Park, M., Chan, A., Aaronson, S., & Vande Woude, G. F. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.11.5152 · Cited by 312
Holbeck, S. L., Collins, J. M., & Doroshow, J. H. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0106 · Cited by 311
Modeling Genomic Diversity and Tumor Dependency in Malignant Melanoma
Lin, W. M., Baker, A. C., Beroukhim, R., Winckler, W., Feng, W., Marmion, J. M., Laine, E., Greulich, H., Tseng, H., Gates, C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2615 · Cited by 297
Self-citationLi, A., Walling, J., Kotliarov, Y., Center, A., Steed, M. E., Ahn, S. J., Rosenblum, M., Mikkelsen, T., Zenklusen, J. C., & Fine, H. A. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0280 · Cited by 264
Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Dry, J. R., Pavey, S., Pratilas, C. A., Harbron, C., Runswick, S., Hodgson, D., Chresta, C., McCormack, R., Byrne, N., Cockerill, M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1577 · Cited by 262
Arimidex�: A potent and selective fourth-generation aromatase inhibitor
Plourde, P. V., Dyroff, M., & Dukes, M. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00682745 · Cited by 258
Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions
Sos, M. L., Michel, K., Zander, T., Weiss, J., Frommolt, P., Peifer, M., Li, D., Ullrich, R., Koker, M., Fischer, F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37127 · Cited by 258
Sos, M. L., Fischer, S., Ullrich, R., Peifer, M., Heuckmann, J. M., Koker, M., Heynck, S., Stückrath, I., Weiss, J., Fischer, F., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907325106 · Cited by 254
Self-citationPharmacology of novel steroidal inhibitors of cytochrome P45017 (17α-hydroxylase/C17–20 lyase)
Barrie, S. E., Potter, G. A., Goddard, P. M., Haynes, B. P., Dowsett, M., & Jarman, M. (1994) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(94)90131-7 · Cited by 253
Bhatnagar, A. S., Häusler, A., Schieweck, K., Lang, M., & Bowman, R. (1990) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(90)90460-3 · Cited by 246
CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma.
Wainstein, M. A., He, F., Robinson, D. R., Kung, H., Schwartz, S., Giaconia, J. M., Edgehouse, N. L., Pretlow, T. P., Bodner, D. R., & Kursh, E. D. (1994) · PubMed · Cited by 244
From basic research to clinical development of MEK1/2 inhibitors for cancer therapy
Frémin, C., & Meloche, S. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-8 · Cited by 243
(1949) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1949.tb68027.x · Cited by 215
Rutman, R. J., CANTAROW, A., & Paschkis, K. E. (1954) · PubMed · Cited by 196
Yeh, J. J., Routh, E. D., Rubinas, T., Peacock, J., Martin, T. D., Shen, X. J., Sandler, R. S., Kim, H. J., Keku, T. O., & Der, C. J. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0972 · Cited by 172
Bussey, K. J., Chin, K., Lababidi, S., Reimers, M., Reinhold, W. C., Kuo, W.-L., Gwadry, F., Ajay, Kouros-Mehr, H., Fridlyand, J., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0155 · Cited by 169
Sasai, K., Romer, J. T., Lee, Y., Finkelstein, D., Fuller, C., McKinnon, P. J., & Curran, T. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4505 · Cited by 155
Ellis, W. J., Vessella, R. L., Buhler, K. R., Bladou, F., True, L. D., Bigler, S. A., Curtis, D., & Lange, P. H. (1996) · PubMed · Cited by 153
Molecular Target Class Is Predictive of In vitro Response Profile
Greshock, J., Bachman, K. E., Degenhardt, Y. Y., Jing, J., Wen, Y. H., Eastman, S., McNeil, E., Moy, C., Wegrzyn, R., Auger, K., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3788 · Cited by 123
1-Amino-4-benzylphthalazines as Orally Bioavailable Smoothened Antagonists with Antitumor Activity
Miller, K. M., Peukert, S., Jain, R. K., McEwan, M. A., Karki, R., Llamas, L., Yusuff, N., He, F., Li, Y., Sun, Y., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900309j · Cited by 104
Predicting Cancer Drug Response by Proteomic Profiling
Ma, Y., Ding, Z., Qian, Y., Shi, X., Castranova, V., Harner, E. J., & Guo, L. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0290 · Cited by 96
Drew, Y., & Plummer, R. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.10.001 · Cited by 88
Zhou, Y., Rideout, W. M., Zi, T., Bressel, A., Reddypalli, S., Rancourt, R. C., Woo, J.-K., Horner, J. W., Chin, L., Chiu, M. I., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1595 · Cited by 88
ACTINOMYCIN D IN CHILDHOOD CANCER
Pinkel, D. P. (1959) · PEDIATRICS · doi:10.1542/peds.23.2.342 · Cited by 82
Leteurtre, F., Kohlhagen, G., Paull, K. D., & Pommier, Y. G. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.16.1239 · Cited by 74
Actinomycin D in childhood cancer; a preliminary report.
Pinkel, D. P. (1959) · PubMed · Cited by 70
Establishment and characterization of a new human prostatic cancer cell line: DuCaP.
Lee, Y.-G., Korenchuk, S., Lehr, J. E., Whitney, S. C., Vessela, R., & Pienta, K. J. (2001) · PubMed · Cited by 52
Dual inhibition of topoisomerase II and tubulin polymerization by azatoxin, a novel cytotoxic agent
Solary, É., Leteurtre, F., Paull, K. D., Scudiero, D. A., Hamel, E., & Pommier, Y. G. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90226-m · Cited by 48
Rutman, R. J., CANTAROW, A., & Paschkis, K. E. (1954) · PubMed · Cited by 28
Gene expression patterns within cell lines are predictive of chemosensitivity
Ring, B. Z., Chang, S., Ring, L. W., Seitz, R. S., & Ross, D. T. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-74 · Cited by 18
Looking for a Target On Every Tumor
Kaiser, J. (2009) · Science · doi:10.1126/science.326_218 · Cited by 14
The effect of actinomycin D on experimental ascitic tumors in the mouse.
Gregory, F. J., HATA, T., PUGH, L. H., & Thielen, R. (1956) · PubMed · Cited by 11
Research works printed but not linked: 2
- Fantini, A., Moser, L., Partridge, R. & Halliday, J. L. The effect of actinomycin D on several mouse tumors. Proc. Am. Assoc. Cancer Res. 2, 108 (1956).
- Farber, S. Carcinolytic action of antibiotics: puromycin and actinomycin D. Am. J. Pathol. 31, 582 (1955).
Cited by
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Self-citationDrost, J., & Clevers, H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0007-6 · Cited by 1,790
Organs-on-chips at the frontiers of drug discovery
Esch, E. W., Bahinski, A., & Huh, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4539 · Cited by 1,185
The placebo response in medicine: minimize, maximize or personalize?
Enck, P., Bingel, U., Schedlowski, M., & Rief, W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3923 · Cited by 671
Discovery of small molecule cancer drugs: Successes, challenges and opportunities
Hoelder, S., Clarke, P. A., & Workman, P. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.004 · Cited by 587
“…xenografts have been used extensively and when selected to exhibit the relevant molecular characteristics and pathogenic drivers can mimic many of the features and response to targeted drugs of the corresponding human cancers (Caponigro and Sellers, 2011; Ocana et al., 2011; Workman et al., 2010).”
BackgroundInfluential
Metadata
- Authors
- Caponigro, G., & Sellers, W. R.
- Corresponding author
- Caponigro, Giordano
- ORCID
- Sellers, William R.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-03
- Volume
- 10
- Issue
- 3
- Pages
- 179-187
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2091336659
- Cited by
- 165
- References
- 89
- Citations by year
- 2026: 3 · 2025: 13 · 2024: 8 · 2023: 11 · 2022: 14 · 2021: 18 · 2020: 10 · 2019: 15 · 2018: 7 · 2017: 4 · 2016: 16 · 2015: 6 · 2014: 10 · 2013: 12 · 2012: 14
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis Institutes for BioMedical Research
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Keywords
- preclinical cancer models, translational oncology, anticancer drug development, drug attrition, clinical trial failure, patient selection
- MeSH terms
- Animals, Antineoplastic Agents, Disease Models, Animal, Drug Evaluation, Preclinical, Genetic Engineering, Humans, Models, Biological, Neoplasms, Cell Line, Tumor, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.